Full Press Release Details
Microbot Medical Secures Design Patent Grant in Europe for the LIBERTY
Mass., September 6, 2022 - Demonstrating another key achievement, Microbot Medical Inc. (Nasdaq:
MBOT), continues to execute its objective of expanding its global intellectual property (IP) portfolio for the LIBERTY
Robotic System as a grant for two Design Patent Applications was issued by the European Patent Office (EPO), covering the LIBERTY Robotic
System's Robotic Drive and Remote Controller.
"The innovative nature of the LIBERTY Robotic System continues
to be recognized by global jurisdictions and reflected in our continuing ability to secure a sustainable competitive advantage by growing
our Intellectual Property portfolio," commented Harel Gadot, Chairman, CEO and President. "This will allow us to continue
leveraging our core capabilities to support our vision to allow accessibility to robotics and meet the demand of physicians, hospitals
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical
medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial
lumens within the human body. Microbot's current proprietary technological platforms provide the foundation for the development
of a Multi Generation Pipeline Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham,
and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic
technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.
Statements to future financial and/or operating results, future growth
in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements
that are not historical fact (including, but not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects" and "estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent
in the development and/or commercialization of potential products, including LIBERTY and SCS, the outcome of its studies to evaluate LIBERTY,
SCS and other existing and future technologies, any failure or inability to recruit physicians and clinicians to serve as primary investigators
to conduct the SCS's early feasibility study which could adversely affect or delay such study, uncertainty in the results of pre-clinical
and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability
to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can
be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange
Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent or obligation
to update these forward-looking statements, except as required by law.